Elite in Scleroderma

Dr. M B. Kahaleh

Rheumatology
University Of Toledo Physicians LLC
3355 Glendale Ave, 
Toledo, OH 
Accepting New Patients
Elite in Scleroderma
University Of Toledo Physicians LLC
3355 Glendale Ave, 
Toledo, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

M Kahaleh is a Rheumatologist in Toledo, Ohio. Dr. Kahaleh is rated as an Elite provider by MediFind in the treatment of Scleroderma. His top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA), and Raynaud Phenomenon. Dr. Kahaleh is currently accepting new patients.

His clinical research consists of co-authoring 37 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 27 articles and participated in 4 clinical trials in the study of Scleroderma.

Specialties
Rheumatology
Licenses
Internal Medicine in OH
Hospital Affiliations
University Of Toledo Medical Center
Mercy St Vincent Medical Center
Promedica Toledo Hospital
Fulton County Health Center
Blanchard Valley Hospital
Languages Spoken
English
Arabic
Arabic - Jordanian
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
McLaren Health
  • HMO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Paramount
  • EPO
  • HMO
  • INDEMNITY
  • PPO
Priority Health
  • HMO
  • POS
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 22 Less Insurance Carriers -

Locations

UNIVERSITY OF TOLEDO PHYSICIANS LLC
3355 Glendale Ave, Toledo, OH 43614

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Drug: Iloprost
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics, and Explore Efficacy of TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics, and Explore Efficacy of TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: June 28, 2024
Intervention Type: Biological, Other
Study Drug: Tepezza Anti-IGF-1 Receptor Monoclonal Antibody
Study Phase: Phase 1
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: March 29, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
View 5 Less Clinical Trials

38 Total Publications

Editorial Expression of Concern: A model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients.
Editorial Expression of Concern: A model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients.
Journal: Arthritis research & therapy
Published: April 01, 2025
Similar Doctors
Elite in Scleroderma
Dr. John J. Varga
Rheumatology
Elite in Scleroderma
Dr. John J. Varga
Rheumatology

Regents Of The University Of Michigan

1500 E Medical Ctr Dr, 
Ann Arbor, MI 
 (46.8 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Varga is a Rheumatologist in Ann Arbor, Michigan. Dr. Varga is rated as a Distinguished provider by MediFind in the treatment of Scleroderma. His top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Scleroma, and Localized Scleroderma. Dr. Varga is currently accepting new patients.

Distinguished in Scleroderma
Dr. Nezam I. Altorok
Rheumatology
Distinguished in Scleroderma
Dr. Nezam I. Altorok
Rheumatology

University Of Toledo Physicians LLC

3125 Transverse Dr, 
Toledo, OH 
 (0.4 miles away)
419-383-5000
Experience:
16+ years
Languages Spoken:
English, Arabic, Arabic - Jordanian
See accepted insurances
Accepting New Patients
Offers Telehealth

Nezam Altorok is a Rheumatologist in Toledo, Ohio. Dr. Altorok has been practicing medicine for over 16 years and is rated as a Distinguished provider by MediFind in the treatment of Scleroderma. His top areas of expertise are Scleroderma, Rhizomelic Pseudopolyarthritis, Polymyalgia Rheumatica, Endoscopy, and Gastrostomy. Dr. Altorok is currently accepting new patients.

Distinguished in Scleroderma
Dr. Dinesh H. Khanna
Rheumatology
Distinguished in Scleroderma
Dr. Dinesh H. Khanna
Rheumatology

Regents Of The University Of Michigan

1500 E Medical Ctr Dr, 
Ann Arbor, MI 
 (46.8 miles away)
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients

Dinesh Khanna is a Rheumatologist in Ann Arbor, Michigan. Dr. Khanna is rated as a Distinguished provider by MediFind in the treatment of Scleroderma. His top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Scleroma, and Scleredema. Dr. Khanna is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kahaleh's expertise for a condition
ConditionClose
View All 15 Advanced Conditions
View All 38 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile